Study 1a Antifungal Prophylaxis in HSCT Recipients With GVHD |
Study 2b Antifungal Prophylaxis in AML or MDS Patients With Neutropenia |
|||||
---|---|---|---|---|---|---|
Deaths, n (%) | POS n=301 | FLU n=299 | log-Rank Test P value | POS n=304 | FLU or ITZ n=298 | log-Rank Test P value |
All cause mortality | 76 (25) | 84 (28) | .376 | 44 (15) | 64 (22) | .035 |
IFI-related | 4 (1) | 12 (4) | .046 | 5 (2) | 15 (5) | .021 |
Deaths reported at end of study (day 168).
Deaths reported up to 100 day postrandomisation (censoring time)